IL248102B - aav vectors for gene therapy of the central nervous system and retina - Google Patents

aav vectors for gene therapy of the central nervous system and retina

Info

Publication number
IL248102B
IL248102B IL248102A IL24810216A IL248102B IL 248102 B IL248102 B IL 248102B IL 248102 A IL248102 A IL 248102A IL 24810216 A IL24810216 A IL 24810216A IL 248102 B IL248102 B IL 248102B
Authority
IL
Israel
Prior art keywords
amino acid
raav
nucleic acid
capsid
acid substitutions
Prior art date
Application number
IL248102A
Other languages
English (en)
Hebrew (he)
Other versions
IL248102A0 (en
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53189202&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL248102(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of IL248102A0 publication Critical patent/IL248102A0/en
Publication of IL248102B publication Critical patent/IL248102B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/015—Parvoviridae, e.g. feline panleukopenia virus, human parvovirus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14145—Special targeting system for viral vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
IL248102A 2014-05-02 2015-05-02 aav vectors for gene therapy of the central nervous system and retina IL248102B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461988131P 2014-05-02 2014-05-02
US201562114575P 2015-02-10 2015-02-10
PCT/US2015/028966 WO2015168666A2 (en) 2014-05-02 2015-05-02 Aav vectors for retinal and cns gene therapy

Publications (2)

Publication Number Publication Date
IL248102A0 IL248102A0 (en) 2016-11-30
IL248102B true IL248102B (en) 2022-07-01

Family

ID=53189202

Family Applications (2)

Application Number Title Priority Date Filing Date
IL248102A IL248102B (en) 2014-05-02 2015-05-02 aav vectors for gene therapy of the central nervous system and retina
IL292951A IL292951B2 (en) 2014-05-02 2015-05-02 Aav vectors for retinal and cns gene therapy

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL292951A IL292951B2 (en) 2014-05-02 2015-05-02 Aav vectors for retinal and cns gene therapy

Country Status (32)

Country Link
US (3) US10982228B2 (enExample)
EP (3) EP3137497B2 (enExample)
JP (4) JP6741591B2 (enExample)
KR (3) KR20160147974A (enExample)
CN (2) CN114231563B (enExample)
AU (3) AU2015252797C1 (enExample)
CA (1) CA2946593A1 (enExample)
CL (2) CL2016002713A1 (enExample)
CR (1) CR20160555A (enExample)
DK (1) DK3137497T4 (enExample)
DO (1) DOP2016000280A (enExample)
EA (1) EA034355B1 (enExample)
ES (1) ES2879636T5 (enExample)
FI (1) FI3137497T4 (enExample)
GT (1) GT201600227A (enExample)
HR (1) HRP20211024T4 (enExample)
HU (1) HUE054768T2 (enExample)
IL (2) IL248102B (enExample)
LT (1) LT3137497T (enExample)
MX (2) MX2016014220A (enExample)
MY (1) MY188987A (enExample)
PE (1) PE20170260A1 (enExample)
PH (1) PH12016502046A1 (enExample)
PL (1) PL3137497T5 (enExample)
PT (1) PT3137497T (enExample)
RS (1) RS62078B2 (enExample)
SG (3) SG11201607991WA (enExample)
SI (1) SI3137497T2 (enExample)
TW (1) TWI686476B (enExample)
UY (1) UY36106A (enExample)
WO (1) WO2015168666A2 (enExample)
ZA (1) ZA201606763B (enExample)

Families Citing this family (179)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9217155B2 (en) 2008-05-28 2015-12-22 University Of Massachusetts Isolation of novel AAV'S and uses thereof
DK3421603T3 (da) 2009-05-02 2022-01-10 Genzyme Corp Genterapi for neurodegenerative forstyrrelser
US8734809B2 (en) 2009-05-28 2014-05-27 University Of Massachusetts AAV's and uses thereof
CA2833912C (en) 2010-04-23 2021-09-21 University Of Massachusetts Aav-based treatment of cholesterol-related disorders
WO2011133874A1 (en) 2010-04-23 2011-10-27 University Of Massachusetts Multicistronic expression constructs
JP5963743B2 (ja) 2010-04-23 2016-08-03 ユニバーシティ オブ マサチューセッツ Ｃｎｓターゲティングａａｖベクターおよびその使用方法
US8663624B2 (en) 2010-10-06 2014-03-04 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
US9226976B2 (en) 2011-04-21 2016-01-05 University Of Massachusetts RAAV-based compositions and methods for treating alpha-1 anti-trypsin deficiencies
MX349138B (es) 2011-04-22 2017-07-13 Univ California Variones de virus adeno-asociados con capside variante y sus metodos de uso.
CN115120746A (zh) 2013-05-15 2022-09-30 明尼苏达大学董事会 腺相关病毒介导的基因向中枢神经系统转移
CA2907799A1 (en) 2013-05-31 2014-12-04 The Regents Of The University Of California Adeno-associated virus variants and methods of use thereof
EP3044318B1 (en) 2013-09-13 2019-05-01 California Institute of Technology Selective recovery
US10072251B2 (en) 2014-02-19 2018-09-11 University Of Massachusetts Recombinant AAVS having useful transcytosis properties
KR102288849B1 (ko) 2014-03-17 2021-08-12 애드베룸 바이오테크놀로지스, 인코포레이티드 원추세포에서 증강된 유전자 발현을 위한 조성물 및 방법
US10280418B2 (en) 2014-03-18 2019-05-07 Univeristy Of Massachusetts RAAV-based compositions and methods for treating amyotrophic lateral sclerosis
WO2015164786A1 (en) 2014-04-25 2015-10-29 University Of Massachusetts Recombinant aav vectors useful for reducing immunity against transgene products
PT3137497T (pt) 2014-05-02 2021-07-12 Genzyme Corp Vetores de aav para terapia genética na retina e snc
JP6634073B2 (ja) * 2014-05-14 2020-01-22 エステベ ファーマシューティカルズ, ソシエダッド アノニマEsteve Pharmaceuticals, S.A. リソソーム蓄積症処置用のアデノ随伴ウイルスベクター
US10689653B2 (en) 2014-06-03 2020-06-23 University Of Massachusetts Compositions and methods for modulating dysferlin expression
WO2016054554A1 (en) 2014-10-03 2016-04-07 University Of Massachusetts Heterologous targeting peptide grafted aavs
JP6842410B2 (ja) 2014-10-03 2021-03-17 ユニバーシティ オブ マサチューセッツ 新規の高効率ライブラリーにより同定されるａａｖベクター
WO2016065001A1 (en) 2014-10-21 2016-04-28 University Of Massachusetts Recombinant aav variants and uses thereof
HK1247641A1 (zh) 2015-02-10 2018-09-28 Genzyme Corporation 变体RNAi
LT3256594T (lt) 2015-02-10 2022-02-10 Genzyme Corporation Patobulintas virusinių dalelių tiekimas į dryžuotąjį kūną ir smegenų žievę
EP3256170B1 (en) 2015-02-13 2020-09-23 University of Massachusetts Compositions and methods for transient delivery of nucleases
JP7095994B2 (ja) 2015-03-02 2022-07-05 アドヴェラム バイオテクノロジーズ， インコーポレイテッド ポリヌクレオチドを網膜錐体に硝子体内送達するための組成物及び方法
AU2016228751B2 (en) * 2015-03-11 2022-01-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Rp2 vectors for treating x-linked retinitis pigmentosa
CA2979065A1 (en) 2015-03-24 2016-09-29 The Regents Of The University Of California Adeno-associated virus variants and methods of use thereof
DK3280432T3 (da) 2015-04-06 2021-04-26 Subdomain Llc Polypeptider indeholdende de novo-bindingsdomæner og anvendelser deraf
WO2016164642A1 (en) 2015-04-08 2016-10-13 The United States Of America, As Represented By The Secretary Of Health And Human Services Viral gene therapy as treatment for cholesterol storage disease or disorder
TWI707951B (zh) 2015-04-08 2020-10-21 美商健臻公司 過大腺相關載體之製造
WO2016172008A1 (en) 2015-04-24 2016-10-27 University Of Massachusetts Modified aav constructions and uses thereof
GB201508026D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Capsid
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
CA2996420A1 (en) 2015-09-28 2017-04-06 The University Of North Carolina At Chapel Hill Methods and compositions for antibody-evading virus vectors
DK3364997T5 (da) 2015-10-22 2024-09-30 Univ Massachusetts Aspartoacylase genterapi til behandling af canavans sygdom
EP3364996B1 (en) 2015-10-22 2021-08-25 University of Massachusetts Prostate-targeting adeno-associated virus serotype vectors
US20180230489A1 (en) 2015-10-28 2018-08-16 Voyager Therapeutics, Inc. Regulatable expression using adeno-associated virus (aav)
CA3007495C (en) * 2015-12-11 2023-04-11 California Institute Of Technology Targeting peptides for directing adeno-associated viruses (aavs)
IL259964B (en) * 2015-12-15 2022-09-01 Genzyme Corp Adenovirus-associated vectors for the treatment of mucolipodosis type ii
EP3411059A4 (en) 2016-02-02 2019-10-16 University Of Massachusetts METHOD FOR INCREASING THE EFFECTIVENESS OF THE SYSTEMIC DELIVERY OF AVV GENES TO THE CENTRAL NERVOUS SYSTEM
US11060088B2 (en) 2016-02-12 2021-07-13 University Of Massachusetts Anti-angiogenic miRNA therapeutics for inhibiting corneal neovascularization
WO2017147477A1 (en) * 2016-02-26 2017-08-31 University Of Florida Research Foundation, Inc. Aav heparin mutants that display significantly improved eye and brain transduction
EP3440210A4 (en) 2016-04-05 2019-11-27 University of Massachusetts COMPOSITIONS AND METHOD FOR SELECTIVELY INHIBITING THE EXPRESSION OF GRAINYHEAD LIKE PROTEIN
CN107287238B (zh) * 2016-04-11 2020-10-16 厦门继景生物技术有限责任公司 一种基因载体及其用于治疗雷柏氏先天性黑矇2型疾病的基因治疗药物
US11413356B2 (en) 2016-04-15 2022-08-16 University Of Massachusetts Methods and compositions for treating metabolic imbalance
GB201608046D0 (en) 2016-05-09 2016-06-22 Cambridge Entpr Ltd And Syndey Children S Hospitals Network Randwick And Westmead Incorporating The Treatment of complement-mediated disorders
SG11201809643UA (en) 2016-05-18 2018-12-28 Voyager Therapeutics Inc Compositions and methods of treating huntington's disease
US11882815B2 (en) 2016-06-15 2024-01-30 University Of Massachusetts Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells
WO2018009814A1 (en) * 2016-07-08 2018-01-11 The Trustees Of The University Of Pennsylvania Methods and compositions for treatment of disorders and diseases involving rdh12
WO2018011572A1 (en) * 2016-07-12 2018-01-18 The University Of Manchester Gene therapy
CN116286986A (zh) 2016-07-29 2023-06-23 加利福尼亚大学董事会 具有变异衣壳的腺相关病毒病毒体和其使用方法
US20190262373A1 (en) * 2016-08-16 2019-08-29 The University Of North Carolina At Chapel Hill Methods and compositions for targeted gene transfer
EP3500667A4 (en) * 2016-08-18 2020-09-02 The Regents of the University of California GENOMIC ENGINEERING OF CRISPR-CAS THROUGH A MODULAR AAV DELIVERY SYSTEM
US20210283222A1 (en) * 2016-08-19 2021-09-16 Calimmune, Inc. Methods and compositions for treating canine conditions using recombinant self-complementary adeno-associated virus
JP7165410B2 (ja) * 2016-08-19 2022-11-04 ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイティド 組換え自己相補的アデノ随伴ウイルスを使用して疾患を治療するための方法及び組成物
US10457940B2 (en) 2016-09-22 2019-10-29 University Of Massachusetts AAV treatment of Huntington's disease
MX392374B (es) 2016-09-28 2025-03-24 Cohbar Inc Peptidos terapeuticos relacionados con mots-c.
US11078238B2 (en) 2016-09-29 2021-08-03 University Of Florida Research Foundation, Incorporated AAVrh.10 variants with host antibody escape capabilities and altered tissue targeting properties
AU2017341849B2 (en) 2016-10-13 2024-03-21 University Of Massachusetts AAV capsid designs
EP3528785A4 (en) 2016-10-19 2020-12-02 Adverum Biotechnologies, Inc. MODIFIED AAV CASPIDS AND USES THEREOF
CA3046347A1 (en) 2016-12-07 2018-06-14 University Of Florida Research Foundation, Incorporated Il-1ra cdnas
WO2018145009A1 (en) * 2017-02-06 2018-08-09 University Of Tennessee Research Foundation Dna-zyme based methods & compositions for treating huntington's disease
WO2018156892A1 (en) 2017-02-23 2018-08-30 Adrx, Inc. Peptide inhibitors of transcription factor aggregation
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
US10898585B2 (en) 2017-04-14 2021-01-26 Ptc Therapeutics .Inc. Gene therapy for AADC deficiency
WO2018200419A1 (en) * 2017-04-23 2018-11-01 The Trustees Of The University Of Pennsylvania Viral vectors comprising engineered aav capsids and compositions containing the same
MX2019013172A (es) * 2017-05-05 2020-09-07 Voyager Therapeutics Inc Composiciones y metodos para tratar la enfermedad de huntington.
EP3622073A4 (en) 2017-05-09 2021-01-06 University of Massachusetts Methods of treating amyotrophic lateral sclerosis (als)
AU2018265414B2 (en) 2017-05-10 2022-01-20 Massachusetts Eye And Ear Infirmary Methods and compositions for modifying assembly-activating protein (APP)-dependence of viruses
CA3066077A1 (en) 2017-06-07 2018-12-13 Adrx, Inc. Tau aggregation inhibitors
AU2018290954B2 (en) * 2017-06-30 2023-07-13 The Regents Of The University Of California Adeno-associated virus virions with variant capsids and methods of use thereof
AU2018311069A1 (en) * 2017-08-03 2020-02-20 Voyager Therapeutics, Inc. Compositions and methods for delivery of AAV
EP3676373A4 (en) 2017-08-28 2021-06-09 The Regents of The University of California Adeno-associated virus capsid variants and methods of use thereof
EP3684937A4 (en) 2017-09-22 2021-06-02 University of Massachusetts NEW DUAL SOD1 EXPRESSION VECTORS AND RELATED USES
US20200377887A1 (en) * 2017-09-22 2020-12-03 Voyager Therapeutics, Inc. Compositions and methods of treating huntington's disease
EP3684932A1 (en) 2017-09-22 2020-07-29 Genzyme Corporation Variant rnai
AU2018350700B2 (en) * 2017-10-16 2025-04-24 Vigeneron Gmbh AAV vectors
WO2019077159A1 (en) * 2017-10-20 2019-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) METHODS OF EXPRESSING POLYNUCLEOTIDE OF INTEREST IN CONE PHOTORECCEPTORS OF A SUBJECT COMPRISING SUB-RETINAL ADMINISTRATION OF A THERAPEUTICALLY EFFECTIVE AMOUNT OF A RECOMBINANT AAV9 DERIVATIVE VECTOR
US11464803B2 (en) 2017-11-14 2022-10-11 Arcellx, Inc. D-domain containing polypeptides and uses thereof
IL274677B2 (en) 2017-11-14 2025-01-01 Arcellx Inc Therapies with multifunctional immune system cells
WO2019097454A1 (en) * 2017-11-15 2019-05-23 Friedrich Miescher Institute For Biomedical Research Primate retinal pigment epithelium cell-specific promoter
MY204271A (en) * 2017-11-15 2024-08-20 Ucl Business Ltd Viral vectors comprising rdh12 coding regions and methods of treating retinal dystrophies
JP7522656B2 (ja) 2017-11-21 2024-07-25 クリスパー セラピューティクス アーゲー 常染色体優性網膜色素変性の処置のための材料および方法
CN108085316B (zh) * 2017-12-25 2021-02-09 中国人民解放军第四军医大学 一种通过抑制微小核糖核酸来促进小鼠视网膜前体细胞体外扩增的方法
US20210017509A1 (en) * 2018-03-23 2021-01-21 The Trustees Of Columbia University In The City Of New York Gene Editing for Autosomal Dominant Diseases
CA3094465A1 (en) 2018-04-03 2019-10-10 Stridebio, Inc. Virus vectors for targeting ophthalmic tissues
SG11202009451VA (en) 2018-04-03 2020-10-29 Stridebio Inc Antibody-evading virus vectors
CN112272672A (zh) 2018-04-03 2021-01-26 斯特里迪比奥公司 抗体逃避性病毒载体
MX2020011386A (es) 2018-04-27 2021-01-29 Spacecraft Seven Llc Terapia genica para la degeneracion del snc.
WO2019222329A1 (en) 2018-05-15 2019-11-21 Voyager Therapeutics, Inc. Compositions and methods for delivery of aav
EP3794126A1 (en) 2018-05-15 2021-03-24 Voyager Therapeutics, Inc. Compositions and methods for the treatment of parkinson's disease
EP3813845A4 (en) 2018-05-15 2022-10-26 President And Fellows Of Harvard College Viral vectors exhibiting improved gene delivery properties
WO2019222444A2 (en) 2018-05-16 2019-11-21 Voyager Therapeutics, Inc. Directed evolution
EP3802836A4 (en) * 2018-06-01 2022-10-19 University of Florida Research Foundation, Incorporated COMPOSITIONS AND METHODS FOR THE TREATMENT OF DOMINANT RETINITIS PIGMENTOSA
WO2019236995A1 (en) 2018-06-08 2019-12-12 University Of Massachusetts Antisense oligonucleotides to restore dysferlin protein expression in dysferlinopathy patient cells
AR114540A1 (es) 2018-08-03 2020-09-16 Genzyme Corp VARIANTE DE ARNi CONTRA a-SINUCLEÍNA
CN109022487A (zh) * 2018-08-15 2018-12-18 上海市第人民医院 一种表达p65的基因载体及其用于治疗视网膜神经节细胞变性的基因治疗药物
JP7624724B2 (ja) 2018-09-26 2025-01-31 カリフォルニア インスティテュート オブ テクノロジー 標的遺伝子療法のためのアデノ随伴ウイルス組成物
SG11202103151RA (en) 2018-09-28 2021-04-29 Voyager Therapeutics Inc Frataxin expression constructs having engineered promoters and methods of use thereof
CA3115782A1 (en) * 2018-10-10 2020-04-16 Wisconsin Alumni Research Foundation Kir 7.1 gene therapy vectors and methods of using the same
EP3863662A1 (en) * 2018-10-12 2021-08-18 Genzyme Corporation Generation of improved human pah for treatment of severe pku by liver-directed gene replacement therapy
US20210371470A1 (en) 2018-10-12 2021-12-02 Voyager Therapeutics, Inc. Compositions and methods for delivery of aav
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
US20230061069A1 (en) * 2018-11-13 2023-03-02 Jayandharan Giridhara Rao A process for producing a plurality of sumoylation target-site modified aav vector and product thereof
CN113227126A (zh) * 2018-11-26 2021-08-06 巴塞罗那自治大学 成纤维细胞生长因子21(fgf21)基因治疗
WO2020117715A1 (en) 2018-12-03 2020-06-11 Board Of Regents, The University Of Texas System Oligo-benzamide analogs and their use in cancer treatment
US20220089670A1 (en) * 2018-12-28 2022-03-24 University Of Rochester Gene Therapy for BEST1 Dominant Mutations
PT3906066T (pt) * 2019-01-04 2024-02-06 Ultragenyx Pharmaceutical Inc Constructos de terapia génica para o tratamento da doença de wilson
CA3125770A1 (en) 2019-01-18 2020-07-23 Voyager Therapeutics, Inc. Methods and systems for producing aav particles
WO2020154535A1 (en) * 2019-01-23 2020-07-30 University Of Florida Research Foundation, Incorporated Highly efficient transduction and lateral spread in the retina by a novel aav virus enhanced by rational design
EP3917944A1 (en) 2019-01-28 2021-12-08 Cohbar Inc. Therapeutic peptides
PT3850089T (pt) 2019-02-04 2024-01-24 Freeline Therapeutics Ltd Polinucleótidos
JP7597380B2 (ja) * 2019-03-04 2024-12-10 アドヴェラム バイオテクノロジーズ， インコーポレイテッド 対側眼へのａａｖ遺伝子治療の逐次的硝子体内投与
US12491264B2 (en) 2019-03-04 2025-12-09 Duke University Compositions and methods for the diagnosis and treatment of retinopathies
WO2020182722A1 (en) * 2019-03-08 2020-09-17 Universite Paris-Saclay Improved therapeutic method for rare ocular diseases by gene replacement
SG11202110146VA (en) 2019-03-21 2021-10-28 Stridebio Inc Recombinant adeno-associated virus vectors
MX2021012184A (es) * 2019-04-10 2022-01-24 Prevail Therapeutics Inc Terapias genicas para trastornos lisosomales.
EP3966227A1 (en) 2019-05-07 2022-03-16 Voyager Therapeutics, Inc. Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
EP3969070A4 (en) * 2019-05-13 2022-07-06 University of Pittsburgh - of the Commonwealth System of Higher Education POLYMER-BASED RETINA THERAPY IMPLANT AND METHOD OF MAKING AND USE THEREOF
AU2020278960A1 (en) * 2019-05-17 2021-12-23 Research Institute At Nationwide Children's Hospital Optimized gene therapy targeting retinal cells
KR20220035107A (ko) * 2019-06-10 2022-03-21 호몰로지 메디슨, 인크. Arsa 유전자 전달을 위한 아데노-연관 바이러스 조성물 및 이의 사용 방법
CA3144986A1 (en) 2019-06-27 2020-12-30 University Of Florida Research Foundation, Incorporated Enhancing aav-mediated transduction of ocular tissues with hyaluronic acid
US11446084B2 (en) 2019-07-12 2022-09-20 Neuralink Corp. Laser drilling of pia mater
RS66255B1 (sr) * 2019-07-15 2024-12-31 Meiragtx Uk Ii Ltd Modifikovani proteini aav kapsida za lečenje artritične bolesti
CN110295151A (zh) * 2019-07-17 2019-10-01 博鑫仪器(天津)有限公司 一类腺依赖病毒病毒重组质粒、重组病毒及构建方法
EP4017873A4 (en) * 2019-08-23 2023-12-20 Duke University COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL PAIN AND ITCH
US20220324921A1 (en) * 2019-09-03 2022-10-13 University Of Cincinnati Methods and compositions for the treatment of als
WO2021046155A1 (en) 2019-09-03 2021-03-11 Voyager Therapeutics, Inc. Vectorized editing of nucleic acids to correct overt mutations
JP2022551487A (ja) * 2019-10-10 2022-12-09 ソリッド・バイオサイエンシーズ・インコーポレーテッド 改変されたａａｖカプシドおよびその使用
EP4045525A1 (en) * 2019-10-17 2022-08-24 Stridebio, Inc. Adeno-associated viral vectors for treatment of niemann-pick disease type c
AU2020369570A1 (en) * 2019-10-23 2022-05-12 The Trustees Of The University Of Pennsylvania Compositions for DRG-specific reduction of transgene expression
WO2021092300A1 (en) * 2019-11-08 2021-05-14 President And Fellows Of Harvard College Viral capsid polypeptides
CN113025618B (zh) * 2019-12-24 2024-02-06 朗信启昇(苏州)生物制药有限公司 一种x连锁遗传性视网膜劈裂症的基因治疗方案与应用
KR20220133941A (ko) * 2020-01-29 2022-10-05 젠자임 코포레이션 안과 유전자 치료를 위한 변형 아데노-관련 바이러스 캡시드 단백질 및 이의 사용 방법
US20230070477A1 (en) * 2020-02-07 2023-03-09 The Trustees Of Culumbia University In The City Of New York Reprogramming the metabolome to delay onset or treat neurodegeneration
WO2021167919A1 (en) * 2020-02-18 2021-08-26 The University Of North Carolina At Chapel Hill Aav capsid-promoter interactions and cell selective gene expression
WO2021173984A2 (en) * 2020-02-28 2021-09-02 University Of Massachusetts Oligonucleotides for prnp modulation
IL296262A (en) * 2020-03-11 2022-11-01 Massachusetts Eye & Ear Infirmary Gene therapy for nmnat1-related retinal degeneration
KR20230113689A (ko) * 2020-03-31 2023-08-01 유니버시티 오브 매사추세츠 Aav 캡시드 변이체 및 그의 용도
CA3174863A1 (en) * 2020-04-14 2021-10-21 Ana BUJ BELLO Vectors for the treatment of acid ceramidase deficiency
KR20230020394A (ko) 2020-04-15 2023-02-10 보이저 테라퓨틱스, 인크. Tau 결합 화합물
IL298001A (en) 2020-05-13 2023-01-01 Voyager Therapeutics Inc Redirecting tropism of adeno-associated virus capsids
WO2021247995A2 (en) 2020-06-04 2021-12-09 Voyager Therapeutics, Inc. Compositions and methods of treating neuropathic pain
JP2023529503A (ja) * 2020-06-13 2023-07-10 オクロジェネクス インコーポレイテッド 網膜症のためのａａｖ媒介性遺伝子導入
CN113952472A (zh) * 2020-07-21 2022-01-21 英斯培瑞有限公司 用于治疗眼部疾病的组合物和方法
WO2022017630A1 (en) 2020-07-23 2022-01-27 Ucl Business Ltd GENE THERAPY VECTOR FOR eEF1A2 AND USES THEREOF
US20230285596A1 (en) 2020-07-27 2023-09-14 Voyager Therapeutics, Inc Compositions and methods for the treatment of niemann-pick type c1 disease
AU2021315876A1 (en) 2020-07-27 2023-02-23 Voyager Therapeutics, Inc. Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
BR112023001336A2 (pt) 2020-08-05 2023-02-14 Spacecraft Seven Llc Terapia gênica de csrp3 (proteína 3 rica em cisteína e glicina)
AU2021320902A1 (en) 2020-08-07 2023-04-06 Spacecraft Seven, Llc Plakophilin-2 (PKP2) gene therapy using AAV vector
TW202227632A (zh) 2020-08-19 2022-07-16 美商史崔德生物公司 用於治療雷特症候群之腺相關病毒載體
CN116249541A (zh) * 2020-09-04 2023-06-09 俄亥俄州创新基金会 具有增强的转导效率并在脑中广泛分布的重组腺相关病毒载体的新型工程化衣壳血清型
WO2022087238A1 (en) * 2020-10-21 2022-04-28 Wisconsin Alumni Research Foundation Anti-apoptotic vector and method of using the same
US20220160825A1 (en) * 2020-11-25 2022-05-26 The Penn State Research Foundation Brain repair after traumatic brain injury through neurod1-mediated astrocyte-to-neuron conversion
KR20230148207A (ko) * 2021-02-22 2023-10-24 더 리전츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코퍼레이트 안구 병태에 대한 바이러스 벡터-기반 유전자 요법
CN115044614B (zh) * 2021-03-09 2023-10-20 上海目镜生物医药科技有限公司 一种用于基因靶向与表达的aav-8型血清型的改造型载体及其构建方法及应用
US20240218396A1 (en) * 2021-04-26 2024-07-04 Grace Science, Llc Compositions and methods for treating ngyl1 deficiency
EP4399314A4 (en) * 2021-09-06 2025-09-10 Huidagene Therapeutics Singapore Pte Ltd TREATMENT OF EYE DISEASES AND DISORDERS ASSOCIATED WITH RPE65
EP4433490A2 (en) 2021-11-17 2024-09-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
JP2024543918A (ja) 2021-11-29 2024-11-26 上海瑞宏迪医薬有限公司 Ａａｄｃ、ｇｄｎｆポリヌクレオチド及びそのパーキンソン病を治療するための使用
CA3244192A1 (en) 2022-02-21 2025-01-22 Shanghai Regenelead Therapies Co Ltd VEGF-BINDING MOLECULE AND ITS PHARMACEUTICAL USE
EP4499154A1 (en) * 2022-03-25 2025-02-05 REGENXBIO Inc. Dominant-negative tumor necrosis factor alpha adeno-associated virus gene therapy
EP4511482A1 (en) * 2022-04-19 2025-02-26 Shanghai Vitalgen Biopharma Co., Ltd. Recombinant aav vectors for treating neurodegenerative disorders
EP4514949A1 (en) 2022-04-25 2025-03-05 Hadasit Medical Research Services&Development Ltd. Methods and compositions for treating vision loss
EP4514402A2 (en) * 2022-04-25 2025-03-05 Myrtelle Inc. Treatments of disorders of myelin
CA3255627A1 (en) 2022-05-06 2023-11-09 Novartis Ag NEW VP2 FUSION POLYPEPTIDES OF RECOMBINANT AAV
WO2023240220A1 (en) * 2022-06-09 2023-12-14 The University Of North Carolina At Chapel Hill Aav-sgsh vectors for treatment of mucopolysaccharidosis iiia
WO2023240236A1 (en) 2022-06-10 2023-12-14 Voyager Therapeutics, Inc. Compositions and methods for the treatment of spinal muscular atrophy related disorders
JP2025520967A (ja) 2022-07-08 2025-07-03 オスペダーレ サン ラファエレ エス．アール．エル 導入遺伝子カセット
EP4303226A1 (en) 2022-07-08 2024-01-10 Ospedale San Raffaele S.r.l. Transgene cassettes and epigenetic silencers for the treatment of disorders
WO2024015794A2 (en) * 2022-07-12 2024-01-18 The Research Institute At Nationwide Children's Hospital Adeno-associated virus gene therapy products and methods
WO2024163012A1 (en) 2023-02-02 2024-08-08 Voyager Therapeutics, Inc. Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
WO2024218311A1 (fr) 2023-04-21 2024-10-24 Pulsesight Therapeutics Compositions à base de décorine pour la réparation et la régéneration de l'épithélium pigmentaire de la rétine
GB202306952D0 (en) * 2023-05-11 2023-06-28 Neurochase Innovations Ltd Method
WO2025128817A1 (en) 2023-12-15 2025-06-19 Genzyme Corporation Artificial micrornas targeting tau
WO2025160452A1 (en) 2024-01-25 2025-07-31 Genzyme Corporation Methods for fus-based delivery of viral particles to the brain
WO2025160429A1 (en) 2024-01-26 2025-07-31 Genzyme Corporation Artificial micrornas targeting snca
WO2025160434A1 (en) 2024-01-26 2025-07-31 Genzyme Corporation Artificial micrornas targeting huntington's disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1486567A1 (en) * 2003-06-11 2004-12-15 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Improved adeno-associated virus (AAV) vector for gene therapy
WO2013173129A2 (en) * 2012-05-15 2013-11-21 Avalanche Australia Pty Ltd. Treatment of amd using aav sflt-1

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4692147A (en) 1980-04-02 1987-09-08 Medtronic, Inc. Drug administration device
US5735815A (en) 1993-07-26 1998-04-07 Sentinel Medical, Inc. Method of using fluid jet surgical cutting tool
CA2264482A1 (en) 1996-09-06 1998-03-12 The Trustees Of The University Of Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase
JP2001523959A (ja) 1997-04-21 2001-11-27 ユニバーシティ オブ フロリダ 疾患のリボザイム処置のための物質および方法
US6042579A (en) 1997-04-30 2000-03-28 Medtronic, Inc. Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6989264B2 (en) 1997-09-05 2006-01-24 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
JP2002516295A (ja) 1998-05-27 2002-06-04 アビジェン， インコーポレイテッド Ａａｖベクターの対流増加送達
EP2369002A1 (en) 1999-08-09 2011-09-28 Targeted Genetics Corporation Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms intrastrand base pairs
ES2256265T3 (es) 2000-06-01 2006-07-16 University Of North Carolina At Chapel Hill Vectores de parvovirus duplicados.
US6723551B2 (en) 2001-11-09 2004-04-20 The United States Of America As Represented By The Department Of Health And Human Services Production of adeno-associated virus in insect cells
GB2389791B (en) 2002-04-30 2006-12-13 Steven Gill Implantable drug delivery pump
AU2004226961B2 (en) * 2002-05-01 2009-06-11 University Of Florida Research Foundation, Inc. VP2-modified rAAV vector compositions and uses therefor
NZ561656A (en) 2002-05-01 2009-03-31 Univ Florida Improved rAAV expression systems for genetic modification of specific capsid proteins
US20060093589A1 (en) * 2004-02-19 2006-05-04 Warrington Kenneth H Vp2-modified raav vector compositions and uses therefor
PT1625210E (pt) 2003-05-21 2011-03-15 Genzyme Corp Métodos para produzir preparações de vírions de aav recombinantes substancialmente livres de capsídeos vazios
EP2657248B1 (en) * 2003-06-19 2017-03-22 Genzyme Corporation AAV virions with decreased immunoreactivity and uses therefor
JP4838255B2 (ja) 2004-10-05 2011-12-14 ジェンザイム・コーポレーション 階段状カニューレ
EP1866422B1 (en) * 2005-04-07 2016-04-06 The Trustees of The University of Pennsylvania Method of increasing the function of an aav vector
CA2619882C (en) 2005-08-23 2015-05-26 The Regents Of The University Of California Reflux resistant cannula and system for chronic delivery of therapeutic agents using convection-enhanced delivery
US7867484B2 (en) * 2006-01-27 2011-01-11 University Of North Carolina At Chapel Hill Heparin and heparan sulfate binding chimeric vectors
HUE030903T2 (en) 2006-04-25 2017-06-28 Univ California Administration of growth factors for the treatment of CNS disorders
US20070259031A1 (en) 2006-04-26 2007-11-08 The Regents Of The University Of California Compositions and methods for convection enhanced delivery of high molecular weight neurotherapeutics
EP2016174A2 (en) 2006-04-28 2009-01-21 The Trustees of the University of Pennsylvania Modified aav vectors having reduced capsid immunogenicity and use thereof
RU2442617C2 (ru) 2007-05-17 2012-02-20 Медженезиз Терапьютикс Инк. Конвекционный доставляющий катетер со съемным элементом жесткости и способ его применения
US20100081707A1 (en) 2008-02-21 2010-04-01 Ali Robin R Devices and methods for delivering polynucleotides into retinal cells of the macula and fovea
US11305022B2 (en) 2009-01-29 2022-04-19 The Regents Of The University Of California Methods for distributing high levels of therapeutic agent throughout the cortex to treat neurological disorders
ES2634118T3 (es) * 2009-02-11 2017-09-26 The University Of North Carolina At Chapel Hill Vectores de virus modificados y métodos para fabricar y utilizar los mismos
HUE054940T2 (hu) 2009-06-16 2021-10-28 Genzyme Corp Javított eljárások rekombináns AAV-vektorok tisztítására
JP5963743B2 (ja) 2010-04-23 2016-08-03 ユニバーシティ オブ マサチューセッツ Ｃｎｓターゲティングａａｖベクターおよびその使用方法
MX349138B (es) 2011-04-22 2017-07-13 Univ California Variones de virus adeno-asociados con capside variante y sus metodos de uso.
WO2015012501A1 (ko) 2013-07-25 2015-01-29 주식회사 스마트캐스터 비공기압 바퀴
GB201403684D0 (en) 2014-03-03 2014-04-16 King S College London Vector
PT3137497T (pt) 2014-05-02 2021-07-12 Genzyme Corp Vetores de aav para terapia genética na retina e snc

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1486567A1 (en) * 2003-06-11 2004-12-15 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Improved adeno-associated virus (AAV) vector for gene therapy
WO2013173129A2 (en) * 2012-05-15 2013-11-21 Avalanche Australia Pty Ltd. Treatment of amd using aav sflt-1

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KERN, A., ET AL., IDENTIFICATION OF A HEPARIN-BINDING MOTIF ON ADENO-ASSOCIATED VIRUS TYPE 2 CAPSIDS., 31 October 2003 (2003-10-31) *
PETRS-SILVA, HILDA, ET AL., NOVEL PROPERTIES OF TYROSINE-MUTANT AAV2 VECTORS IN THE MOUSE RETINA., 28 February 2011 (2011-02-28) *

Also Published As

Publication number Publication date
IL292951A (en) 2022-07-01
DK3137497T4 (da) 2025-05-26
IL292951B1 (en) 2024-06-01
CL2016002713A1 (es) 2017-08-11
JP6741591B2 (ja) 2020-08-19
KR20240032156A (ko) 2024-03-08
US12241078B2 (en) 2025-03-04
EA034355B1 (ru) 2020-01-30
JP2023011812A (ja) 2023-01-24
AU2021200242A1 (en) 2021-03-18
US20250320522A1 (en) 2025-10-16
CN114231563B (zh) 2024-08-16
SI3137497T2 (sl) 2025-07-31
ES2879636T3 (es) 2021-11-22
FI3137497T4 (fi) 2025-06-02
PL3137497T4 (pl) 2023-04-11
TW201625792A (zh) 2016-07-16
PE20170260A1 (es) 2017-04-12
CN106661591B (zh) 2021-10-29
RS62078B2 (sr) 2025-06-30
EA201692206A1 (ru) 2017-03-31
MX2016014220A (es) 2017-02-06
US20210189430A1 (en) 2021-06-24
MY188987A (en) 2022-01-17
ES2879636T5 (en) 2025-06-13
JP7682142B2 (ja) 2025-05-23
AU2021200242B2 (en) 2023-09-21
EP3137497B2 (en) 2025-03-05
IL248102A0 (en) 2016-11-30
PT3137497T (pt) 2021-07-12
HUE054768T2 (hu) 2021-09-28
AU2023285817A1 (en) 2024-01-18
AU2015252797C1 (en) 2021-04-22
DOP2016000280A (es) 2016-11-30
PL3137497T5 (pl) 2025-06-09
US20170096683A1 (en) 2017-04-06
EP4600255A3 (en) 2025-10-22
KR20160147974A (ko) 2016-12-23
AU2021200242B9 (en) 2023-10-05
BR112016025263A2 (pt) 2018-02-20
IL292951B2 (en) 2024-10-01
EP4600255A2 (en) 2025-08-13
JP2017518271A (ja) 2017-07-06
GT201600227A (es) 2018-01-22
WO2015168666A2 (en) 2015-11-05
TWI686476B (zh) 2020-03-01
UY36106A (es) 2015-11-30
AU2015252797A1 (en) 2016-11-17
PL3137497T3 (pl) 2021-10-25
EP3913061A1 (en) 2021-11-24
SG11201607991WA (en) 2016-10-28
DK3137497T3 (da) 2021-07-12
KR102863726B1 (ko) 2025-09-25
KR20250141850A (ko) 2025-09-29
RS62078B1 (sr) 2021-07-30
MX2022012490A (es) 2022-10-27
SG10201912977RA (en) 2020-02-27
US10982228B2 (en) 2021-04-20
EP3137497A2 (en) 2017-03-08
EP3137497B1 (en) 2021-04-07
HRP20211024T1 (hr) 2021-10-01
JP2025065116A (ja) 2025-04-17
ZA201606763B (en) 2023-05-31
CA2946593A1 (en) 2015-11-05
CL2018000170A1 (es) 2018-06-29
CN114231563A (zh) 2022-03-25
SI3137497T1 (sl) 2021-08-31
WO2015168666A3 (en) 2015-12-23
PH12016502046A1 (en) 2017-02-06
AU2015252797B2 (en) 2020-10-15
JP2020164540A (ja) 2020-10-08
LT3137497T (lt) 2021-07-26
SG10201809739QA (en) 2018-12-28
HRP20211024T4 (hr) 2025-06-20
CR20160555A (es) 2017-01-27
JP7174011B2 (ja) 2022-11-17
CN106661591A (zh) 2017-05-10

Similar Documents

Publication Publication Date Title
US20250320522A1 (en) Aav vectors for retinal and cns gene therapy
HK40064049A (en) Aav vectors for retinal and cns gene therapy
HK40071052A (en) Aav vectors for retinal and cns gene therapy
HK40071052B (zh) 用於视网膜及cns基因疗法的aav载体
HK1234076B (en) Aav vectors for retinal and cns gene therapy
BR112016025263B1 (pt) Usos: de uma partícula de vírus adenoassociado recombinante (raav), de um kit, e de uma composição compreendendo uma partícula de vírus adenoassociado recombinante (raav)
BR122020026753B1 (pt) Uso de uma partícula de vírus adenoassociado recombinante (raav) na fabricação de um medicamento para distribuir um ácido nucleico heterólogo ao olho de um indivíduo